Business Wire

Jefferies to Coordinate Global Effort to Support Hurricane Relief in the Bahamas

9.9.2019 15:00:00 EEST | Business Wire | Press release

Share

Jefferies announced today that the firm and its staff will contribute to the relief efforts to assist those in the Bahamas suffering from the devastation caused by Hurricane Dorian and will offer investors around the world the opportunity to join these efforts.

First, Jefferies will donate all net trading commissions on Wednesday, September 11 from U.S., European and Asia equity, fixed income and foreign exchange trading. Second, Jefferies as a firm will donate $1 million itself directly. Finally, all 3,656 employees worldwide will be given the opportunity to donate to the relief effort their salary for the day on Wednesday. These contributions will be allocated to a series of charities with the goal of quickly getting funds to relief efforts directly involved in the rescue and recovery efforts.

Rich Handler, Chairman and Chief Executive Officer of Jefferies, and Brian Friedman, Chairman of the Executive Committee, commented: "All of us at Jefferies are deeply concerned about the catastrophic devastation in the Bahamas. We hope this donation from Jefferies will help, in some small way, to ease the pain of those affected and encourage our global employees and clients to join our efforts to contribute to those in need.”

Jefferies Group LLC, the largest independent full-service global investment banking firm headquartered in the U.S. focused on serving clients for over 55 years, is a leader in providing insight, expertise and execution to investors, companies and governments. Our firm provides a full range of investment banking, advisory, sales and trading, research and wealth management services across all products in the Americas, Europe and Asia. Jefferies Group LLC is a wholly owned subsidiary of Jefferies Financial Group Inc. (NYSE: JEF), a diversified financial services company.

For further information, please contact your Jefferies representative.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media inquiries, please contact:
Richard Khaleel, +1 212 284 2556, rkhaleel@jefferies.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bureau Veritas: A Steady Organic Revenue Growth in the First Quarter 202622.4.2026 08:30:00 EEST | Press release

Bureau Veritas (BOURSE:BVI): Q1 2026 Key figures1 › Revenue of EUR 1,547.0 million, up 4.5% organically, and down 0.8% year-on-year › Strong organic growth from Marine & Offshore at +11.2% and Buildings & Infrastructure at +7.3% with moderate growth for Consumer Products Services at +4.3%, Certification at +2.3%, Agri-Food & Commodities at +2.1%, and Industry at +0.7%, › Stable scope effect of (0.1)%, from bolt-on acquisitions (+1.8% contribution), net of disposals (-1.9%), › Negative currency impact of 5.2%, resulting from the euro’s appreciation against most currencies. Q1 2026 Highlights › Maintained steady performance across most regions, in an environment marked by disruptions related to the conflict in the Middle East; growth in the Industry business impacted by the delays of Opex-related services mainly in the Middle East, › Continued progress in execution of the Group’s LEAP | 28 strategy, pivoting its portfolio towards higher‑growth and higher‑margin activities. Four acquisiti

Bureau Veritas: A Steady Organic Revenue Growth in the First Quarter 202622.4.2026 08:30:00 EEST | Press release

Bureau Veritas (BOURSE:BVI): Q1 2026 Key figures1 › Revenue of EUR 1,547.0 million, up 4.5% organically, and down 0.8% year-on-year › Strong organic growth from Marine & Offshore at +11.2% and Buildings & Infrastructure at +7.3% with moderate growth for Consumer Products Services at +4.3%, Certification at +2.3%, Agri-Food & Commodities at +2.1%, and Industry at +0.7%, › Stable scope effect of (0.1)%, from bolt-on acquisitions (+1.8% contribution), net of disposals (-1.9%), › Negative currency impact of 5.2%, resulting from the euro’s appreciation against most currencies. Q1 2026 Highlights › Maintained steady performance across most regions, in an environment marked by disruptions related to the conflict in the Middle East; growth in the Industry business impacted by the delays of Opex-related services mainly in the Middle East, › Continued progress in execution of the Group’s LEAP | 28 strategy, pivoting its portfolio towards higher‑growth and higher‑margin activities. Four acquisiti

4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis22.4.2026 08:00:00 EEST | Press release

4Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis Drugs (DMOADs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to 4P004 for the treatment of knee osteoarthritis in patients with synovitis who have not benefited from at least two prior pharmacological therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421591087/en/ 4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis This designation highlights both the serious burden of knee osteoarthritis and the persistent lack of disease-modifying treatment options. It also reflects the strong scientific rationale supporting the 4P004 development program, including its targeted intra-articular approach and the role of synovitis as a key marker of disease progression. 4P004 is a

4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis22.4.2026 08:00:00 EEST | Press release

4Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis Drugs (DMOADs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to 4P004 for the treatment of knee osteoarthritis in patients with synovitis who have not benefited from at least two prior pharmacological therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421591087/en/ 4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis This designation highlights both the serious burden of knee osteoarthritis and the persistent lack of disease-modifying treatment options. It also reflects the strong scientific rationale supporting the 4P004 development program, including its targeted intra-articular approach and the role of synovitis as a key marker of disease progression. 4P004 is a

LTM Wins Two Google Cloud Partner of the Year Awards for 202622.4.2026 05:30:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, announced today that it has received two Google Cloud Partner of the Year 2026 Awards. LTM is being recognized for its achievements in the Google Cloud ecosystem, helping joint customers to drive high-impact, scalable cloud transformations. LTM won the Google Cloud Partner of the Year Award in the Media & Entertainment category by modernizing a global media company's complex data estate with BigQuery. The transformation improved speed, lowered costs, and provided a scalable foundation, enabling real-time analytics and AI-ready pipelines. This approach offers a repeatable model for data modernization in Media and Entertainment industry. Additionally, LTM was honoured with another Google Cloud Partner of the Year Award for Infrastructure Modernization in North America and the transformation of the ERP landscape for a global leader in healthcare services. This resulted in faster time to market, modern scalable ecosys

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye